Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
100 employees
US-based Verastem, Inc. develops and commercializes cancer and tumor treatments, serving healthcare professionals.
HQ
Founded
2010
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for cancer and tumor growth. Specializing in RAF, MEK, and focal adhesion kinase (FAK) inhibition, Verastem aims to provide innovative solutions for patients and healthcare professionals in the United States.
Verastem has made significant strides in the oncology field, contributing to advancements in cancer treatment. The company's efforts have been recognized within the medical community, enhancing its reputation as a leader in targeted cancer therapies.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Treatments
Technology
Biotech
Tags
Healthtech
Model Types
Retail, Software
Revenue Type(s)
Transactional, Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was Verastem founded?
Verastem was founded in 2010.
Where is Verastem's headquarters located?
Verastem's headquarters is located in Boston, MA, US.
When was Verastem's last funding round?
Verastem's most recent funding round was for $60M (USD) in January 2023.
How many employees does Verastem have?
Verastem has 100 employees as of Feb 6, 2024.
How much has Verastem raised to-date?
As of July 05, 2023, Verastem has raised a total of $280M (USD) since Jan 24, 2023.
Add Comparison
Total Raised to Date
$280M
USD
Last Update Jan 24, 2023
Last Deal Details
$60M
USD
Jan 24, 2023
Post Ipo Equity
Current Employees
100
Last updated: Feb 6, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts